A few of the things tha stood out for me following the webinar:
- Expectation for all 12 patients to continue taking monepantel, delays due to ethics approvals
- 60 -80 days from today for orphan drug status approval
- PH2 study received positive feedback from FDA and plan to start Q2 2024
- Will begin pre-clinical study for Alzheimer's and Parkinson's
-10mg is optimal dose, any higher results in a small benefit which is not worth risking superior safety profile
As one might say, lovely jubbly
Ann: PharmAust to present at NWR Virtual Healthcare Conference, page-9
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.3¢ | 19.0¢ | $25.41K | 133.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5372 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 262575 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |